Rachel Neuwirth

1.7k total citations
47 papers, 1.2k citations indexed

About

Rachel Neuwirth is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Rachel Neuwirth has authored 47 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 25 papers in Hematology and 15 papers in Oncology. Recurrent topics in Rachel Neuwirth's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (14 papers) and Cancer Treatment and Pharmacology (11 papers). Rachel Neuwirth is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (14 papers) and Cancer Treatment and Pharmacology (11 papers). Rachel Neuwirth collaborates with scholars based in United States, Canada and Netherlands. Rachel Neuwirth's co-authors include Paul G. Richardson, Pieter Sonneveld, Sagar Lonial, Donna Reece, Hartmut Goldschmidt, Thierry Façon, Michael W. Schuster, Dina Ben‐Yehuda, Kathleen Ford and Asher Chanan‐Khan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Rachel Neuwirth

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Neuwirth United States	18	689	615	454	125	108	47	1.2k
Armin Zebisch Austria	19	895 1.3×	411 0.7×	331 0.7×	143 1.1×	28 0.3×	57	1.5k
Lia Perez United States	22	322 0.5×	940 1.5×	441 1.0×	179 1.4×	20 0.2×	80	1.3k
Prince George United States	6	945 1.4×	231 0.4×	142 0.3×	85 0.7×	82 0.8×	9	1.2k
Elisabeth Ersvær Norway	24	639 0.9×	584 0.9×	282 0.6×	128 1.0×	37 0.3×	58	1.3k
Nicholas Davies United Kingdom	15	584 0.8×	86 0.1×	298 0.7×	116 0.9×	51 0.5×	25	1000
Kathy Chun Canada	22	742 1.1×	630 1.0×	315 0.7×	204 1.6×	17 0.2×	59	1.6k
Kourosh Lotfi Sweden	18	400 0.6×	383 0.6×	264 0.6×	283 2.3×	14 0.1×	54	968
Kumar Vivek United States	11	416 0.6×	199 0.3×	145 0.3×	95 0.8×	144 1.3×	20	1.0k
Jan Philipp Bewersdorf United States	26	707 1.0×	1.1k 1.9×	372 0.8×	425 3.4×	18 0.2×	137	1.8k
Simone Silberman United States	17	483 0.7×	137 0.2×	347 0.8×	63 0.5×	46 0.4×	41	1.2k

Countries citing papers authored by Rachel Neuwirth

Since Specialization

Citations

This map shows the geographic impact of Rachel Neuwirth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Neuwirth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Neuwirth more than expected).

Fields of papers citing papers by Rachel Neuwirth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Neuwirth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Neuwirth. The network helps show where Rachel Neuwirth may publish in the future.

Co-authorship network of co-authors of Rachel Neuwirth

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Neuwirth. A scholar is included among the top collaborators of Rachel Neuwirth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Neuwirth. Rachel Neuwirth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naylor, Maria L., Rachel Neuwirth, Abraham Avigdor, & Tomas Olsson. (2024). Safety, tolerability, pharmacodynamics, and pharmacokinetics of oral TAK-861 in an acute sleep phase delay paradigm in healthy male subjects. Sleep Medicine. 115. S225–S225.

Han, Sileny, Amit M. Oza, Nicoletta Colombo, et al.. (2023). A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer. Gynecologic Oncology. 178. 110–118. 7 indexed citations

Bottino, Dean, Jilai Zhou, Chirag Patel, et al.. (2019). Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling. Clinical Cancer Research. 25(22). 6633–6643. 17 indexed citations

Hanley, Michael J., Diane R. Mould, Tim Taylor, et al.. (2017). Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. The Journal of Clinical Pharmacology. 57(9). 1183–1193. 14 indexed citations

Burris, Howard A., Carla Kurkjian, L. Hart, et al.. (2017). TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 80(2). 261–273. 39 indexed citations

Kumar, Shaji, et al.. (2017). Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma. British Journal of Haematology. 178(5). 756–763. 22 indexed citations

Tang, Min, Rui Zhao, Helgi van de Velde, et al.. (2016). Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research. 22(16). 4206–4214. 20 indexed citations

Rasco, Drew, Anthony J. Olszanski, Amita Patnaik, et al.. (2013). MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.. Journal of Clinical Oncology. 31(15_suppl). 2547–2547. 7 indexed citations

Solh, Melhem, Richard I. Fisher, André Goy, et al.. (2013). Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leukemia & lymphoma. 54(10). 2185–2189. 4 indexed citations

10.

Infante, Jeffrey R., Josep Tabernero, Andrés Cervantes, et al.. (2013). Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.. Molecular Cancer Therapeutics. 12(11_Supplement). C252–C252. 15 indexed citations

11.

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2013). Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416). Blood. 122(21). 1966–1966. 12 indexed citations

12.

Niesvizky, Rubén, Ian W. Flinn, N. Gabrail, et al.. (2011). Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study.. Journal of Clinical Oncology. 29(15_suppl). 8072–8072. 1 indexed citations

13.

Miguel, Jesús F. San, Paul G. Richardson, Robert Z. Orlowski, et al.. (2011). Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). Blood. 118(21). 2933–2933. 8 indexed citations

14.

Reece, Donna, Dan M. Sullivan, Sagar Lonial, et al.. (2010). Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology. 67(1). 57–67. 94 indexed citations

15.

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2010). Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients. Blood. 116(21). 619–619. 27 indexed citations

16.

Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, et al.. (2009). “Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. Biology of Blood and Marrow Transplantation. 16(1). 70–77. 5 indexed citations

17.

Venkatakrishnan, Karthik, Michael Rader, Ramesh K. Ramanathan, et al.. (2009). Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study. Clinical Therapeutics. 31. 2444–2458. 53 indexed citations

18.

Miguel, Jesús F. San, Paul G. Richardson, Pieter Sonneveld, et al.. (2008). Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 22(4). 842–849. 130 indexed citations

19.

Zangari, Maurizio, Dixie Esseltine, Federica Cavallo, et al.. (2007). Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients. American Journal of Hematology. 82(9). 831–833. 23 indexed citations

20.

Warren, Katherine E., Mahendra Patel, Alberta Aikin, et al.. (2001). Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemotherapy and Pharmacology. 48(4). 275–282. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact